Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers i...
Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: An interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials
About this item
Full title
Author / Creator
Publisher
Belle Mead, NJ: EM Inc USA
Journal title
Language
English
Formats
Publication information
Publisher
Belle Mead, NJ: EM Inc USA
Subjects
More information
Scope and Contents
Contents
Abstract Background: Exenatide, an incretin mimetic for adjunctive treatment of type 2 diabetes mellitus (T2DM), reduced glycosylated hemoglobin (HbA1c ) and weight in 30-week placebo-controlled trials. Some patients were followed up in open-label extensions to provide ‘real-world’ exenatide clinical experience. Objective: The purpose of this study...
Alternative Titles
Full title
Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: An interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_1032921529
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_1032921529
Other Identifiers
ISSN
0149-2918
E-ISSN
1879-114X
DOI
10.1016/j.clinthera.2007.01.015
